ELUT drug-eluting biomatrix nears expected FDA clearance
ELUT’s drug-eluting biomatrix platform for breast reconstruction targets high infection rates, with regulatory clearance for NXT-41 expected in Q4 2024 and NXT-41x following in 2027; the platform is supported by $54 million in secured capital and surgeon demand.